1. Home
  2. PRAX vs BOC Comparison

PRAX vs BOC Comparison

Compare PRAX & BOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRAX
  • BOC
  • Stock Information
  • Founded
  • PRAX 2015
  • BOC 2009
  • Country
  • PRAX United States
  • BOC United States
  • Employees
  • PRAX N/A
  • BOC N/A
  • Industry
  • PRAX Biotechnology: Pharmaceutical Preparations
  • BOC
  • Sector
  • PRAX Health Care
  • BOC
  • Exchange
  • PRAX Nasdaq
  • BOC Nasdaq
  • Market Cap
  • PRAX 599.7M
  • BOC 482.8M
  • IPO Year
  • PRAX 2020
  • BOC 2017
  • Fundamental
  • Price
  • PRAX $38.55
  • BOC $14.70
  • Analyst Decision
  • PRAX Strong Buy
  • BOC Buy
  • Analyst Count
  • PRAX 10
  • BOC 2
  • Target Price
  • PRAX $116.50
  • BOC $20.00
  • AVG Volume (30 Days)
  • PRAX 320.6K
  • BOC 107.5K
  • Earning Date
  • PRAX 05-02-2025
  • BOC 05-14-2025
  • Dividend Yield
  • PRAX N/A
  • BOC N/A
  • EPS Growth
  • PRAX N/A
  • BOC N/A
  • EPS
  • PRAX N/A
  • BOC 0.03
  • Revenue
  • PRAX $8,122,000.00
  • BOC $110,452,664.00
  • Revenue This Year
  • PRAX N/A
  • BOC $9.66
  • Revenue Next Year
  • PRAX N/A
  • BOC $6.33
  • P/E Ratio
  • PRAX N/A
  • BOC $546.31
  • Revenue Growth
  • PRAX 270.02
  • BOC 11.58
  • 52 Week Low
  • PRAX $26.70
  • BOC $12.41
  • 52 Week High
  • PRAX $91.83
  • BOC $16.20
  • Technical
  • Relative Strength Index (RSI)
  • PRAX 53.72
  • BOC 47.93
  • Support Level
  • PRAX $35.21
  • BOC $14.11
  • Resistance Level
  • PRAX $38.90
  • BOC $15.10
  • Average True Range (ATR)
  • PRAX 2.09
  • BOC 0.35
  • MACD
  • PRAX 0.07
  • BOC -0.01
  • Stochastic Oscillator
  • PRAX 69.58
  • BOC 37.50

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

About BOC Boston Omaha Corporation

Boston Omaha Corp is a us-based company which invests in real estate. Its operations include its ownership of multiple billboards in Florida, Georgia, Wisconsin, and Alabama and equity method investments in several real estate companies. The company operates four separate lines of business, outdoor billboard advertising, the broadband services industry, the insurance industry, and the asset management industry. They generate revenue from outdoor advertising through the leasing of advertising space on billboards. It also generate revenue from commissions on surety bond sales and account for commissions and principally from internet services and is recognized on a straight-line basis over the term of the contract in the period the services are rendered.

Share on Social Networks: